X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 76.76 CNY -0.7%
Market Cap: 31.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Xiamen Amoytop Biotech Co Ltd stock under the Base Case scenario is 111 CNY. Compared to the current market price of 76.76 CNY, Xiamen Amoytop Biotech Co Ltd is Undervalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
111 CNY
Undervaluation 31%
Relative Value
Price
X
Worst Case
Base Case
Best Case

Valuation Multiples

14
P/S
P/S
Price to Sales
14
vs History
33
vs Industry
45
Median 3Y
10.3
Median 5Y
11.4
Industry
8.1
Forward
11
More Details
52
P/E
P/E
Price to Earnings
52
vs History
61
vs Industry
4
Median 3Y
50.2
Median 5Y
58.9
Industry
23
Forward
39.3
More Details
54.9
P/OCF
P/OCF
Price to OCF
54.9
vs History
44
vs Industry
4
Median 3Y
46.7
Median 5Y
53.6
Industry
23.4
More Details
129.7
P/FCFE
P/FCFE
Price to FCFE
129.7
vs History
56
vs Industry
2
Median 3Y
132.9
Median 5Y
174.4
Industry
27.3
More Details
16.6
P/B
P/B
Price to Book Value
16.6
vs History
16
vs Industry
7
Median 3Y
11.3
Median 5Y
12.3
Industry
2.6
More Details
13.7
EV/S
EV/S
Enterprise Value to Sales
13.7
vs History
33
vs Industry
38
Median 3Y
10
Median 5Y
11.1
Industry
8.1
Forward
10.7
More Details
14.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.7
vs History
33
vs Industry
36
Median 3Y
11.1
Median 5Y
12
Industry
9.6
More Details
42.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
42.3
vs History
46
vs Industry
3
Median 3Y
37.7
Median 5Y
42.5
Industry
4.3
Forward
30
More Details
42.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
42.3
vs History
46
vs Industry
4
Median 3Y
37.7
Median 5Y
42.5
Industry
3.8
Forward
33.9
More Details
53.7
EV/OCF
EV/OCF
Enterprise Value to OCF
53.7
vs History
44
vs Industry
4
Median 3Y
45
Median 5Y
51.8
Industry
6
More Details
127
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
127
vs History
60
vs Industry
2
Median 3Y
129.7
Median 5Y
182.5
Industry
3.8
More Details
18.6
EV/IC
EV/IC
Enterprise Value to IC
18.6
vs History
21
vs Industry
17
Median 3Y
13.1
Median 5Y
14.7
Industry
4.8
More Details

Multiples Across Competitors

Competitors Multiples
Xiamen Amoytop Biotech Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Xiamen Amoytop Biotech Co Ltd
SSE:688278
31.2B CNY 14 52 42.3 42.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
301B USD 5.4 59.2 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 5 38.3 17.8 33.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 12 -265.7 26.9 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 4.1 916 10.2 10.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
138B AUD 6 33.9 20.9 26
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 6.4 19 17.5 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average P/E: 186.4
52
183%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.2
412%
US
Amgen Inc
NASDAQ:AMGN
38.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
916
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average EV/EBITDA: 21.5
42.3
202%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average EV/EBIT: 26.1
42.3
143%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
26
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 198,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.